Structure Therapeutics' (GPCR) "Sell (D-)" Rating Reaffirmed at Weiss Ratings

Key Points

• Structure Therapeutics' stock received a "sell (D-)" rating from Weiss Ratings, reaffirming concerns about the company’s performance.
• Despite the negative outlook from Weiss, other brokerages like Cantor Fitzgerald and JMP Securities have issued higher price targets, reflecting mixed analyst sentiments.
• Structure Therapeutics has seen significant changes in institutional ownership, with large investors increasing their stakes in the company, which now has over 91% institutional ownership.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report)'s stock had its "sell (d-)" rating reissued by equities research analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

A number of other brokerages have also commented on GPCR. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, June 23rd. JMP Securities dropped their price target on Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating for the company in a research note on Thursday, August 7th. HC Wainwright dropped their price target on Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Guggenheim lowered their price objective on Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating for the company in a research report on Thursday, August 7th. Finally, Lifesci Capital raised Structure Therapeutics to a "strong-buy" rating in a research report on Monday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Structure Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $68.67.

Structure Therapeutics Stock Performance

Shares of Structure Therapeutics stock opened at $28.45 on Wednesday. The company's 50 day moving average price is $21.24 and its 200-day moving average price is $21.10. Structure Therapeutics has a 52-week low of $13.22 and a 52-week high of $42.57. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of -27.09 and a beta of -1.65.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08). As a group, equities research analysts forecast that Structure Therapeutics will post -0.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

Large investors have recently modified their holdings of the stock. State of Wyoming purchased a new position in shares of Structure Therapeutics in the 2nd quarter worth about $28,000. National Bank of Canada FI raised its position in shares of Structure Therapeutics by 1,448.2% in the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock worth $51,000 after purchasing an additional 2,766 shares during the last quarter. Assetmark Inc. raised its position in shares of Structure Therapeutics by 39.9% in the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company's stock worth $60,000 after purchasing an additional 820 shares during the last quarter. ANTIPODES PARTNERS Ltd raised its position in shares of Structure Therapeutics by 310.7% in the 1st quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company's stock worth $74,000 after purchasing an additional 3,213 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its position in shares of Structure Therapeutics by 29.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company's stock worth $92,000 after purchasing an additional 994 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.